IMvigor210队列一线治疗转移性尿路上皮癌研究.pdfVIP

IMvigor210(Cohort1):First-line

AtezolizumabinCistin-

IneligibleMetastaticUrothelial

Carcinoma

CCOtConferenceCoverage*

ofthe2016ASCOAnnualMeeting,June3-7,2016

*CCOisantmedicaleducationcompanythatprovidesstate-of-the-artmedical

informationtohealthcareprofessionalsthroughconferencecoverageandothereducationalprograms.

ThisactivityissupportedbyeducationalgrantsfromAmgen,Ariad,

BayerHealthcarePharmaceuticals,CelgeneCorporation,Genentech,

Incyte,Merck,andTaihoPharmaceuticals.

IMvigor210(Cohort1):Background

▪Cistintheisfirst-linestandardofcareformetastaticurothelial

carcinoma

‒Mostptsarecistinineligibleduetopoorperformancestatus,impaired

renalfunction,orcomorbidities[1]

‒Non-cistin–basedregimensassociatedwithshortresponseduration,

lackofsurvivalbenefit,highdiscontinuationrate[2]

▪Atezolizumab:engineeredmAbtargetingPD-L1immunecheckpoint

‒Active,welltoleratedintreatment-experiencedmUC[3]

‒CurrentlyFDAapprovedonlyincistin-treatedpts

▪Cohort1oftheIMvigor210studyevaluatedsafety,efficacyof

atezolizumabasfirst-linetherapyinuntreated,cistin-ineligiblemUC

pts[4]

1.GalaskyMD.ECC2015.2624.2.DeSantisM,etal.JClinOncol.

2012;30:191-199.3.RosenbergJE,etal.Lancet.2016;387:1909-1920.

4.BalarAV,etal.ASCO2016.LBA4500.Slidecredit:

IMvigor210:StudyDesign

▪Single-armphaseIIstudywith2cohorts[1]

Ptswithinoperable

Cohort1:(n119)[2]Atezolizumab

advancedor

metastaticUC,previouslyuntreated,1200mgIVQ3W

pre